Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Chronic kidney disease (CKD) affects over 3 million Canadians.
• CKD is strongly linked to cardiovascular diseases requiring anticoagulation, like atrial fibrillation and venous thromboembolism.
• CKD patients experience a high risk of both thrombotic events and bleeding complications from anticoagulation therapy.

Purpose of the Study:

• To review the physiology and epidemiology of bleeding and thrombosis in CKD patients.
• To provide a nephrologist's perspective on anticoagulation in advanced CKD or dialysis patients.
• To offer practical clinical recommendations for anticoagulation use in CKD patients with atrial fibrillation.

Main Methods:

• Literature review focusing on bleeding and thrombosis in kidney disease.
• Analysis of existing evidence for anticoagulation in stroke prevention for atrial fibrillation.
• Examination of specific clinical scenarios relevant to CKD patients.

Main Results:

• Discusses the complex interplay of thrombosis and bleeding risks in CKD.
• Summarizes current evidence on anticoagulation for stroke prevention in CKD patients with atrial fibrillation.
• Highlights challenges in anticoagulation management, including GFR estimation, risk prediction, and drug dosing.

Conclusions:

• Managing anticoagulation in CKD patients presents significant challenges due to competing risks.
• Further research and clear guidelines are needed to optimize anticoagulation strategies in this population.
• Practical recommendations are provided to aid nephrologists in decision-making regarding anticoagulation for CKD patients.